Since OGA inhibition is being considered for long-term AD treatment, we replicated OGA inhibition for 1 month in the 5XFAD Alzheimer’s disease mice which express high APP protein levels. This evidence concerns the gene OGA and early-onset autosomal dominant Alzheimer disease.